Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~1. patient is over 18 years~2. ovarian carcinoma patients who are treated with moderately emetogenic chemotherapy~3. Karnofsky score \> 60~4. Life expectancy \> 4 months~Exclusion criteria~1. Any of following conditions (mentally incapacitated or emotional or psychiatric disorder, user of any illicit drugs, has an active infection, hypersensitivity to ramosetron or aprepitant)~2. Patients have received a nonapproved drug within last 4 weeks~3. abnormal laboratory values (AST \> 2.5 normal, ALT \> 2.5 normal, Bilirubin \> 1.5 normal, Creatinine \> 1.5 normal)~4. Antiemetic drugs within 48 hours of study~5. Benzodiazepine or opiate within 48 hours~6. CYP3A4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide)~7. CYP3A4 inhibitors (clarithromycin, ketoconazole)~8. CYP3A4 inducers within 30 days (Barbiturates, rifampicin, carbamazepine)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).